Cellectis (CLLS) Other Non-Current Assets (2014 - 2026)
Cellectis (CLLS) posted quarterly Other Non-Current Assets of $21.3 million for Q1 2026, up 58.34% year-over-year from $13.4 million in Q1 2025, and up 6.3% quarter-over-quarter from $20.0 million in Q4 2025.
Analysis
Cellectis (CLLS) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Cellectis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $21.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 58.34% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $21.3 million (up 58.34% YoY), while the FY2025 annual figure was $20.0 million, up 72.72% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $21.3 million, up from $20.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $21.3 million in Q1 2026, with the low at $499000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $11.6 million (2024), against an average of $12.3 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slumped 97.74% in 2022, then jumped 3935.07% in 2023.
- Cellectis' Other Non-Current Assets stood at $8.8 million in 2022, then tumbled by 47.04% to $4.7 million in 2023, then soared by 149.01% to $11.6 million in 2024, then soared by 72.72% to $20.0 million in 2025, then gained by 6.3% to $21.3 million in 2026.
- Business Quant data shows CLLS's Other Non-Current Assets at $21.3 million in Q1 2026, $20.0 million in Q4 2025, and $18.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 22.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.73 Mn |
| Mar 31, 2026 | 21.29 Mn |
| Dec 31, 2025 | 20.03 Mn |
| Sep 30, 2025 | 18.18 Mn |
| Jun 30, 2025 | 16.13 Mn |
| Mar 31, 2025 | 13.44 Mn |
| Dec 31, 2024 | 11.59 Mn |
| Sep 30, 2024 | 11.12 Mn |
| Mar 31, 2023 | 20.14 Mn |
| Dec 31, 2022 | 21.77 Mn |
| Mar 31, 2022 | 175,000.00 |
| Sep 30, 2021 | 22.05 Mn |
| Jun 30, 2021 | 22.10 Mn |
| Mar 31, 2021 | 22.11 Mn |
| Dec 31, 2020 | 7.01 Mn |
| Sep 30, 2020 | 9.78 Mn |
| Jun 30, 2020 | 7.38 Mn |
| Mar 31, 2020 | 7.48 Mn |
| Dec 31, 2019 | 5.52 Mn |
| Sep 30, 2019 | 5.47 Mn |